Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00952497 · ClinicalTrials.gov registry record · Phase 2

A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer

A Phase 2 study of Gastric Cancer, sponsored by ACT Biotech.

Completed
Registry status
Phase 2
Development phase
48
Enrollment target
11
Study locations

NCT00952497 is a Phase 2 study of Gastric Cancer that has completed, run by ACT Biotech. The registered enrollment target is 48 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (85% lower). The trial reports 11 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00952497, a Phase 2 study of Gastric Cancer, has completed, sponsored by ACT Biotech.

COMPLETED
Registry status
Phase 2
Development phase
48 participants
Enrollment target
11
Study locations

Study Summary

The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced gastric cancer. The primary objective is to assess progression free survival (PFS) in subjects receiving telatinib in combination with chemotherapy (capecitabine and cisplatin). The secondary objectives are to assess overall survival, overall response rate, safety and tolerability, pharmacokinetics and biomarkers.

Conditions Studied

Gastric Cancer

Interventions

  • DRUG Cisplatin, Capecitabine, Telatinib

Study Locations (11)

Other

  • Hospital Vall d' Hebron - Barcelona
  • Hospital Universitari Germans Trias i Pujol - Barcelona
  • Hospital Universitario Ramon y Cajal - Madrid
  • Hospital Clinico San Carlos - Madrid
  • Hospital Universitario 12 de Octubre - Madrid
  • Hospital Universitario Marques de Valdecilla - Santander

California

  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Georgia

  • Central Georgia Cancer Care, P.C. - Macon

Pennsylvania

  • University of Pennsylvania, Abramson Cancer Center - Philadelphia

Tennessee

  • The West Clinic - Memphis

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2009-06
Est. Completion 2012-01
Phase Phase 2

Sponsor

ACT Biotech

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00952497

The ClinicalTrials.gov registry entry for NCT00952497 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (85% lower). The listed sponsor is ACT Biotech, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cisplatin, Capecitabine, Telatinib is the first listed.

NCT00952497 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT00952497 about?

NCT00952497 is a clinical study titled "A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer". The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced gastric cancer. The primary objective is to assess progression free surv...

What is the current status of trial NCT00952497?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2009-06. Estimated completion is 2012-01.

What conditions does trial NCT00952497 study?

This clinical trial studies the following conditions: Gastric Cancer.

What interventions are being tested in trial NCT00952497?

The interventions under investigation include: Cisplatin, Capecitabine, Telatinib (DRUG).

Who is sponsoring clinical trial NCT00952497?

This trial is sponsored by ACT Biotech, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00952497 being conducted?

This trial has 11 study locations across California, Georgia, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.